There’s quite a bit in the news of late as relates to prostate cancer.  Just last week another drug was approved by the FDA that extends the life of prostate cancer patients which was a very quick review process, an interesting read. 

FDA Approves New Life Prolonging Drug For Men With Late Stage Prostate Cancer - Xtandi

In addition back on track this related article about a research project from Johns Hopkins talks about the use of synthetic collagen to better help identify the location of tumors.  You can see with the picture of the mouse that the locations of prostate and pancreatic cells are lit up as cancer cells attack collagen cells and thus with this methodology the tumors are easier to locate as some of course are not visible to the human eye or with other methodologies of finding them. 

Collagen-Seeking Synthetic Protein Could Lead Doctors to Locate Tumor Locations– Research Funded by NIH, DOD, Process Patented Via Johns Hopkins Technology Transfer Office

You can read the entire press release to see where the awards were given for research and the interesting origin of of the funds for two of the grants by using unclaimed class action lawsuit settlement funds in Massachusetts.  That is a good solution instead of letting the money sit and go nowhere.  Grants in this area are important as they pick up where the government grants and funds leave off and are not available to continue to promote research to lead to better treatments and hopefully on day a cure.  BD

SANTA MONICA, Calif.--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) today announced that it has funded nine new PCF Challenge Awards in an effort to accelerate scientific discovery and new treatments for prostate cancer patients. These nine awards represent a $9 million investment over a two-year period and were chosen from a pool of 96 applications received from researchers in 10 countries.

Prostate Cancer Foundation Challenge Awards are designedimage to support cross-disciplinary teams of investigators in strategic areas of prostate cancer research and highly-innovative research projects with potential near-term patient benefits. These awards are given to projects not yet funded by any government or foundation program. The awards were announced after an extensive peer review process. These projects represent a range of focus and expertise that will address the most challenging problems in basic or translational research in prostate cancer.

“More than 28,000 men will lose their life to advanced prostate cancer in 2012, highlighting the immediate need to fund innovative, collaborative research projects,” said Howard Soule, PhD, executive vice president and chief science officer of the Prostate Cancer Foundation. “These nine Challenge Awards bridge the gap of reductions in federal funding for prostate cancer research, allowing the most promising research ideas to still be funded, with a goal of changing clinical practice and improving outcomes for patients with advanced disease. The Foundation is extremely grateful for the state of Massachusetts, Movember and individual donors who made these awards possible.”


Post a Comment

Google Analytics Alternative